Biogen: positive phase III data in lupus

(CercleFinance.com) - UCB and Biogen have announced positive top-line results from the Phase 3 PHOENYCS GO study evaluating their dapirolizumab pegol in people with moderate-to-severe systemic lupus erythematosus (SLE).


The drug candidate, in addition to standard therapy, met the primary endpoint by demonstrating greater improvement in moderate-to-severe disease activity after 48 weeks, compared with placebo in addition to standard therapy.

Clinical improvements were observed across key secondary endpoints measuring disease activity and relapses. The safety profile of dapirolizumab pegol was generally consistent with previous studies.


Copyright (c) 2024 CercleFinance.com. All rights reserved.